

Why carry out this study?

- In patients with normal tension glaucoma, intraocular pressure (IOP) reductions of 20% may prevent progression of visual field defects.
- Twenty-four hour fluctuations in IOP should also be avoided to help prevent disease progression.
- We examined the 24-hour daytime sustainability of the IOP-lowering efficacy of the prostaglandin analog travoprost 0.004% ophthalmic solution in subjects with normal tension glaucoma at multi center.

What was learned from the study?

- This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost persists during the day at the clinically relevant level in subjects with NTG.
- The ability of travoprost to minimize diurnal fluctuations in IOP means it may be effective in preventing the progression of visual field defects in normal tension glaucoma.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Alcon Japan Ltd. Dr. Daniel McGowan (Springer Healthcare) provided English-language editing, and was funded by Alcon Japan Ltd. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2016. Creative Commons Attribution Noncommercial License (CC BY-NC).